NR607 Standardized Procedure
Worksheet
Student Name:
Carefully read the assignment guidelines and rubric and complete each section of the worksheet below.
1. Definition
a. Disease or
condition Serotonin
syndrome
b. Pathophysiology
Serotonin syndrome is a potentially fatal condition triggered by an excess of
serotonin in the central nervous system. This syndrome leads to heightened
serotonin (5-HT) activity in the CNS and peripheral receptors (Badar, 2024).
This overactivity can result from therapeutic medication use, intentional self-
harm, or accidental drug interactions.
Serotonin syndrome manifests when the CNS retains an excessive amount of
serotonin, leading to receptor overstimulation. As stated by Badar (2024), this
can occur through serotonin production (e.g., L-tryptophan), release (e.g.,
amphetamines), reuptake inhibition (e.g., SSRIs, SNRIs), and degradation
inhibition (e.g., MAOIs). The overstimulation of serotonin receptors results in
various symptoms associated with serotonin syndrome.
c. Incidence and prevalence
The true prevalence of serotonin syndrome (SS) remains ambiguous and is likely
underreported, as its symptoms often resemble those of other conditions, and mild
cases tend to be ignored. The rise in serotonin syndrome occurrences is associated
with the increased consumption of serotonergic drugs, especially SSRIs. In 2016, the
Toxic Exposure Surveillance System recorded 54,410 incidents of SSRI poisoning,
resulting in 102 deaths, with estimates suggesting that around 15% of these could
be attributed to serotonin syndrome (Mikkelsen et al., 2023). Another dataset from
the US reveals an SS incidence between 0.07% and 0.19% (Mikkelsen et al., 2023).
Nevertheless, with the growing use of serotonergic medications, the frequency is
believed to be on the rise and is more commonly seen in patients taking multiple
serotonergic drugs (Prakash et al., 2021). The condition is generally regarded as
, rather rare.
Around 15% of SSRI overdoses result in mild to moderate SS, while severe cases are
uncommon (Chiew & Isbister, 2024). The co-ingestion of moclobemide increases the
risk of SS,
0320 RB/KK
Worksheet
Student Name:
Carefully read the assignment guidelines and rubric and complete each section of the worksheet below.
1. Definition
a. Disease or
condition Serotonin
syndrome
b. Pathophysiology
Serotonin syndrome is a potentially fatal condition triggered by an excess of
serotonin in the central nervous system. This syndrome leads to heightened
serotonin (5-HT) activity in the CNS and peripheral receptors (Badar, 2024).
This overactivity can result from therapeutic medication use, intentional self-
harm, or accidental drug interactions.
Serotonin syndrome manifests when the CNS retains an excessive amount of
serotonin, leading to receptor overstimulation. As stated by Badar (2024), this
can occur through serotonin production (e.g., L-tryptophan), release (e.g.,
amphetamines), reuptake inhibition (e.g., SSRIs, SNRIs), and degradation
inhibition (e.g., MAOIs). The overstimulation of serotonin receptors results in
various symptoms associated with serotonin syndrome.
c. Incidence and prevalence
The true prevalence of serotonin syndrome (SS) remains ambiguous and is likely
underreported, as its symptoms often resemble those of other conditions, and mild
cases tend to be ignored. The rise in serotonin syndrome occurrences is associated
with the increased consumption of serotonergic drugs, especially SSRIs. In 2016, the
Toxic Exposure Surveillance System recorded 54,410 incidents of SSRI poisoning,
resulting in 102 deaths, with estimates suggesting that around 15% of these could
be attributed to serotonin syndrome (Mikkelsen et al., 2023). Another dataset from
the US reveals an SS incidence between 0.07% and 0.19% (Mikkelsen et al., 2023).
Nevertheless, with the growing use of serotonergic medications, the frequency is
believed to be on the rise and is more commonly seen in patients taking multiple
serotonergic drugs (Prakash et al., 2021). The condition is generally regarded as
, rather rare.
Around 15% of SSRI overdoses result in mild to moderate SS, while severe cases are
uncommon (Chiew & Isbister, 2024). The co-ingestion of moclobemide increases the
risk of SS,
0320 RB/KK
